CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones
January 04, 2019 18:15 ET
|
Unum Therapeutics Inc.
In a release issued yesterday under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 has been changed from initiating clinical...
Unum Therapeutics Announces 2019 Goals and Expected Milestones
January 03, 2019 07:00 ET
|
Unum Therapeutics Inc.
- Multiple Data Readouts from ATTCK-20-03 and ATTCK-17-01 Expected in 2019 - - Initial Data on ATTCK-34-01, Unum’s First Program in Solid Tumors, Expected in Second Half of 2019 - - First...
Unum Therapeutics Announces Transition of Chief Financial Officer
January 03, 2019 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies,...
Unum Therapeutics Added to NASDAQ Biotechnology Index
December 20, 2018 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies,...
Unum Therapeutics Announces US Patent Protection for ACTR Technology
December 06, 2018 07:00 ET
|
Unum Therapeutics Inc.
US Patent and Trademark Office Issues US Patent 10,144,770 Covering Antibody-Coupled T-cell Receptors (ACTR)Broad Claims Provide Composition of Matter Protection for Cell Therapies and Their Methods...
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting
December 02, 2018 21:00 ET
|
Unum Therapeutics Inc.
- Complete Responses Observed in Three of Six Patients at Dose Level 1 and One of Three Patients at Dose Level 2 - - No SAEs of Cytokine Release Syndrome or Neurological Events Observed in Dose...
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting
December 01, 2018 21:25 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in...
CORRECTION: Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors
November 12, 2018 18:13 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the investors event date has been...
Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors
November 12, 2018 16:01 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies,...
Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
November 12, 2018 16:01 ET
|
Unum Therapeutics Inc.
- ACTR707 in Combination with Rituximab Selected as Lead Product Candidate for Further Development in r/r NHL – - New Solid Tumors Technology Platform Revealed at SITC – - More Details on Solid...